Catalent (NYSE:CTLT) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Catalent (NYSE:CTLT) in a report released on Saturday. The firm set a “sell” rating on the stock.

Separately, Stephens restated an “equal weight” rating and issued a $63.50 price target on shares of Catalent in a report on Thursday, April 4th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $54.05.

Catalent Stock Up 3.1 %

CTLT opened at $56.50 on Friday. The firm has a 50 day moving average price of $55.51 and a 200 day moving average price of $53.10. The company has a market cap of $10.23 billion, a PE ratio of -9.26, a price-to-earnings-growth ratio of 6.62 and a beta of 1.20. Catalent has a 1 year low of $31.80 and a 1 year high of $60.20. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. Sell-side analysts expect that Catalent will post 0.28 earnings per share for the current year.

Insider Activity

In other news, insider Ricky Hopson sold 1,401 shares of the stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the transaction, the insider now directly owns 20,617 shares in the company, valued at approximately $1,118,678.42. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Catalent

Several large investors have recently added to or reduced their stakes in the company. Lindbrook Capital LLC lifted its stake in Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after purchasing an additional 208 shares during the last quarter. Czech National Bank lifted its stake in Catalent by 0.7% during the first quarter. Czech National Bank now owns 31,801 shares of the company’s stock worth $1,795,000 after purchasing an additional 228 shares during the last quarter. BNP Paribas Asset Management Holding S.A. lifted its stake in Catalent by 1.9% during the fourth quarter. BNP Paribas Asset Management Holding S.A. now owns 17,850 shares of the company’s stock worth $802,000 after purchasing an additional 328 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. increased its position in Catalent by 6.2% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,703 shares of the company’s stock worth $256,000 after buying an additional 331 shares during the period. Finally, Arizona State Retirement System increased its position in Catalent by 0.7% in the fourth quarter. Arizona State Retirement System now owns 49,546 shares of the company’s stock worth $2,226,000 after buying an additional 365 shares during the period.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.